Jefferies Cuts Price Target on Merck (MRK) to $56; Reiterates Hold
- Wall Street falls as bank, healthcare shares weigh
- Qualcomm (QCOM) Faces U.S. Antitrust Case Over Licensing - Bloomberg
- BAT Reaches Deal to Acquire Reynolds American (RAI) for $49 Billion
- Verizon Communications (VZ) May Acquire Big Cable Company - NYP (CHTR) (CMCSA)
- Citron Research Negative on Lannett (LCI); Sees Shares at 'Zero' Over Long Term
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Jefferies reiterated a Hold rating on Merck (NYSE: MRK), and cut the price target to $56.00 (from $57.00), as the company's growth remains constrained.
Analyst Jeffrey Holford commented, "MRK was over-rewarded for the failure of BMY's CM-026 study in our view. Whilst we see a c$3.3bn opportunity for Keytruda in NSCLC it is not enough to drive meaningful growth against upcoming LOEs. We expect competing IO combo data in 2017 will lower investor enthusiasm, though strong growth from Keytruda in Q4'16 may offset this to a degree."
Shares of Merck closed at $62.49 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: JPMorgan Downgrades OneMain (OMF) to Neutral
- Mizuho Securities Raises Price Target on Noble Energy (NBL) to $48; Reiterates Buy
- Stifel Raises Price Target on Las Vegas Sands (LVS) to $66; Reiterates Buy
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!